These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30544783)

  • 1. The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients.
    Lindemann M; Korth J; Sun M; Xu S; Struve C; Werner K; Dornieden T; Horn PA; Witzke O; Wilde B
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients.
    Dornieden T; Wilde B; Korth J; Werner K; Horn PA; Witzke O; Lindemann M
    J Immunol Res; 2019; 2019():3926175. PubMed ID: 30931336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
    Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
    J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
    Barabas S; Spindler T; Kiener R; Tonar C; Lugner T; Batzilla J; Bendfeldt H; Rascle A; Asbach B; Wagner R; Deml L
    BMC Immunol; 2017 Mar; 18(1):14. PubMed ID: 28270111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.
    Banas B; Steubl D; Renders L; Chittka D; Banas MC; Wekerle T; Koch M; Witzke O; Mühlfeld A; Sommerer C; Habicht A; Hugo C; Hünig T; Lindemann M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Krämer BK; Krüger B
    Transpl Int; 2018 Apr; 31(4):436-450. PubMed ID: 29284181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
    Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
    Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.
    Abate D; Saldan A; Forner G; Tinto D; Bianchin A; Palù G
    J Virol Methods; 2014 Feb; 196():157-62. PubMed ID: 24216234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
    Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
    Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomonitoring via ELISPOT Assay Reveals Attenuated T-Cell Immunity to CMV in Immunocompromised Liver-Transplant Patients.
    Traska AK; Nowacki TM; Vollenberg R; Rennebaum F; Meier JA; Schomacher T; Reinartz Groba SN; Fischer J; Trebicka J; Tepasse PR
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.
    Calarota SA; Chiesa A; Scaramuzzi L; Adzasehoun KM; Comolli G; Mangione F; Esposito P; Baldanti F
    J Clin Virol; 2014 Sep; 61(1):65-73. PubMed ID: 24961915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
    Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
    J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
    Lee H; Park KH; Ryu JH; Choi AR; Yu JH; Lim J; Han K; Kim SI; Yang CW; Chung BH; Oh EJ
    PLoS One; 2017; 12(12):e0189488. PubMed ID: 29232714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
    El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
    J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant.
    Kim T; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Korean J Intern Med; 2020 Mar; 35(2):438-448. PubMed ID: 29865778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
    Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
    J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELISPOT assay of interferon-γ secretion for evaluating human cytomegalovirus reactivation risk in allo-HSCT recipients.
    Liang H; Xia J; Zhang R; Yang B; Wu J; Gui G; Huang Y; Chen X; Yang R; Wang H; Gong S; Fan J
    J Med Virol; 2021 Nov; 93(11):6301-6308. PubMed ID: 34076905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
    Chanouzas D; Small A; Borrows R; Ball S
    PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
    Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
    New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-17 ELISpot as Predictor for Kidney Allograft Rejection?
    Lindemann M; Könemann J; Horn PA; Witzke O
    Clin Lab; 2016; 62(5):963-5. PubMed ID: 27349025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.